MSCoreSys Industry Symposium

Europe/Berlin
International Congress Center Dresden - Seminar Room 2 (HUPO2024)

International Congress Center Dresden - Seminar Room 2

HUPO2024

Ostra-Ufer 2 01067 Dresden, Germany
Description

Mass Spectrometry for Systems Medicine, MSCoreSys is a Germany-wide consortium of scientists and clinicians that aims for translation of technical advancements in proteomics, metabolomics and systems medicine into benefit for patients. MSCoreSys is supported by a six-year and 80 M€ grant of the German Federal Ministry of Education and Research (BMBF).

We are pleased to invite you to the MSCoreSys Industry Symposium which will be held as part of the HUPO world congress on Tuesday the 22nd of October from 10 am to 2 pm at ICC Maritim Hotel Dresden. The symposium brings together key stakeholders to discuss how academia, biotech, CROs and industry can synergize to realize the enormous societal potential and economic opportunities in clinical proteomics and metabolomics.

Symposium Highlights:

  • Showcases: Get inspired by the consortium's vision and current achievements.
  • Panel Discussion: Engage in thought-provoking discussions on the future needs, technical solutions and actual future implementation of clinical proteomics and metabolomics in the health care system.
  • Networking: Connect with peers, potential partners, and collaborators.

 

The symposium reconciles the perspectives of academia and industry on systems medicine and will allow you to contribute to shaping the future of clinical proteomics and metabolomics as well as related technologies, reagents and services. 

The Organizing Committee


--> Click here for participating remotely via Zoom



 

Hosts: 

Bernhard Küster, Technical University of Munich, Munich 
Jeroen Krijgsveld, German Cancer Research Center, Heidelberg


 

Supported by:

 

Registration
Register to the MSCoreSys Industry Symposium
Participants
  • Amelie Riederer
  • Eric Grumbach
  • Jenny Samskog
  • Katharina Limm
  • Marijana Marijana
  • Peter Findeisen
  • Stefanie Hauck
  • Stephan H. Bauer
  • Thomas Ristau
  • +8
    • 10:00 10:05
      Welcoming adress: BMBF
      Convener: Ralf Mytzek-Zühlke (BMBF)
    • 10:05 10:15
      Scientific Introduction: Philosophy of MSCoreSys research initiative - Past & Present
      Convener: Ulrich Keilholz
    • 10:15 12:00
      Showcases
      • 10:15
        Technology Development for Systems Medicine 15m
        Speaker: Jeroen Krijgsveld (Deutsches Krebsforschungszentrum)
      • 10:30
        Spatial and single-cell approaches for precision medicine 10m
        Speaker: Fabian Coscia
      • 10:40
        Standardization and Clinical Evaluation of Mass spectrometry in a Multi-center Setting - Fostering the Transition to Clinical Use 15m
        Speaker: Philipp Wild
      • 10:55
        From Discovery to Delivery: Highlights of Public-Private Partnerships and Emerging StartUps 10m
        Speakers: Markus Ralser, Matthias Selbach
      • 11:05
        Model-Driven Clinical Decision Tools Using Mass Spectrometry 15m
        Speaker: Ursula Klingmüller (Deutsches Krebsforschungszentrum)
      • 11:20
        How proteomics adds value to treatment recommendations in molecular tumor boards 15m
        Speakers: Annika Schneider (Chair of Proteomics and Bioanalytics, Technical university Munich), Bernhard Kuster
      • 11:35
        Mass spectrometry in the clinical laboratory - a success story for patients 15m
        Speaker: Katharina Habler
      • 11:50
        The Future of MSCoreSys 10m
        Speaker: Ulrich Keilholz
    • 12:00 12:30
      Lunch Break 30m
    • 12:30 14:00
      Discussion “Future of MSCoreSys”
      Convener: Speakers and Audience
      • 12:30
        The Industry Perspective 45m
        • How do you see the field of (MS-based) systems medicine developing?
        • From an industry perspective, what aspects of initiatives like MSCoreSys are particularly relevant to your work?
        • In what ways could your company contribute to advancing initiatives like MSCoreSys, particularly in moving towards clinical and commercial applications?
        • What do you see as the key factors required to foster successful public-private partnerships aimed at translating mass spectrometry-based technologies into clinical or commercial solutions?
      • 13:15
        Open Discussion 45m